Part 1 of a series on the mission to defy aging.
Category: life extension – Page 409
💯💯Subscribe for videos on becoming superhuman: https://goo.gl/TSDCuv
Timestamps:
- What Causes Aging and Why It Happens 03:00.
- How to Slow Down the Aging Process 08:57.
- Why Do Sirtuin Genes Promote Longevity 11:50.
- Xenohormesis and Resveratrol 13:55
- What is NAD and How It Affects Aging 18:55.
- Different Types of NAD Boosters 20:46
- Signs of Aging 25:00
- How Dr Sinclair Exercises 29:25
- Metformin, mTOR, and Insulin 34:00
- What’s the Upper Limit for Human Lifespan 39:58.
- What Area of Research Is Most Promising 43:58.
David Sinclair Lifespan Book: https://amzn.to/2nb1dds
Use Code MZFALL2019 for a 25% Discount for Bioptimizers Masszymes Digestive Enzymes: https://bit.ly/30PYUud
Podcast About Longevity Pathways: https://www.youtube.com/watch?v=4mDPEoyKQSg
The science isn’t there yet, nor are the known interventions that ought to be combined with delivering such predictions.
In-Silico Clinical Trials — Virtual Bodies For Real Drugs — Dr. William Pruett — University of Mississippi Medical Center — ideaXme — Ira Pastor
Posted in aging, bioengineering, biotech/medical, DNA, futurism, genetics, health, life extension, neuroscience, science | 2 Comments on In-Silico Clinical Trials — Virtual Bodies For Real Drugs — Dr. William Pruett — University of Mississippi Medical Center — ideaXme — Ira Pastor
It was a pleasure speaking to Dr. Ronald Kohanski at the 2019 Ending Age-Related Diseases conference. Dr. Kohanski joined the field of aging research in 2005 as a Program Officer for the Division of Aging Biology at the National Institute on Aging. He moved on to become its Deputy Director in 2007 and has held the position ever since. Within aging research, he has focused his efforts on the areas of stem cell and cardiovascular biology.
Besides his work at the NIA, Ronald Kohanski is a co-founder and co-leader of the trans-NIH Geroscience Interest Group (GSIG) with which he has organized several summits to discuss and disseminate the group’s focus. The GSIG directs its attention toward aging as the major risk factor for most chronic age-related diseases, and Dr. Kohanski actively encourages researchers to expand studies beyond laboratory animals. He underwrites the importance of addressing the basic biology of aging explicitly in human and non-laboratory animal populations. He believes that age should be considered a fundamental parameter in research that uses animal models of chronic disease.
Dr. Kohanski was trained in the field of biochemistry. He received his PhD from the University of Chicago in 1981, after which he conducted a postdoctoral fellowship with M. Daniel Lane at the Johns Hopkins University School of Medicine. He held a faculty position at the Mount Sinai School of Medicine for 17 years before returning to Johns Hopkins as a faculty member and researcher in the areas of enzymology and developmental biology of the insulin receptor.
Dr. Qingsong Zhu, the COO of Insilico Medicine, discussed the use of deep learning in creating biomarkers for aging. Initially discussing existing clocks and the problems with animal translation, he went on to discuss what sorts of markers are ideal for age-related research and the details of training and testing a model that works with these markers, showing that a deep model compares favorably to other models.
He also used his model to show that smoking does, in fact, cause accelerated aging.
Julie Andersen, The Buck Institute, presenting at Undoing Aging 2019.
Connect with Undoing Aging:
Facebook: https://www.facebook.com/events/1077333215804499/
Videos: https://www.undoing-aging.org/videos
News: https://www.undoing-aging.org/news
LinkedIn: https://www.linkedin.com/showcase/12631536/
By and Targeting Metabesity to examine the links between metabesity, Longevity and the USA’s current health shortfalls, including low health-adjusted life expectancy (“HALE”) and the large gap between HALE and life expectancy, despite its extremely high per-capita healthcare expenditures, and to chart policy recommendations to neutralize this vast health vs wealth deficit.
Metabesity and Longevity: USA Special Case Study is an 85-page open-access analytical report produced jointly by Aging Analytics Agency and Targeting Metabesity to examine the links between metabesity, Longevity and the USA s current health shortfalls, including low health-adjusted life expectancy ( HALE ) and the large gap between HALE and life expectancy, despite its extremely high per-capita healthcare expenditures, and to chart policy recommendations to neutralize this vast health vs wealth deficit.
Link to Special Case Study: https://aginganalytics.com/longevity-usa/
As the issue of aging population intensifies, sick care will become increasingly expensive and ineffective. America needs to rapidly deploy a government-led shift from treatment to prevention, and from prevention to precision health, using deep diagnostics and prognostics in combination with biomarkers of aging, metabesity, health and intervention-effectiveness, to delay the onset of disease with as minimal intervention as possible, as early as possible. Seeking synergies between Longevity research, P4 (preventive, personalized, precision and participatory) medicine and Artificial Intelligence has the potential to enable rapid and widespread policy and infrastructural reforms for USA healthcare to quickly boost National Healthy Longevity, but only with sufficient government commitment.
We’re continuing to release talks from Ending Age-Related Diseases 2019, our highly successful two-day conference that featured talks from leading researchers and investors, bringing them together to discuss the future of aging and rejuvenation biotechnology.
Dr. Peter Fedichev, co-founder of GERO, discussed biomarkers in the context of mouse research, particularly physiological frailty and blood cell counts. He introduced a new index, the Dynamic Frailty Index, and explained it in detail, including the advantages that it has over conventional frailty models and epigenetic clocks. He also explained the differences between humans and mice, most notably the fact that interventions that work in mice do not always apply to human beings.